WallStSmart

BlackRock Inc (BLK)vsBlackRock Health Sciences Trust II (BMEZ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BLK leads profitability with a 24.4% profit margin vs 0.0%. BMEZ trades at a lower P/E of 5.7x. BLK earns a higher WallStSmart Score of 78/100 (B+).

BLK

Strong Buy

78

out of 100

Grade: B+

Growth: 8.7Profit: 7.5Value: 5.7Quality: 7.0
Piotroski: 2/9Altman Z: 1.13

BMEZ

Avoid

30

out of 100

Grade: F

Growth: 3.3Profit: 4.0Value: 6.7Quality: 6.0
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BLK6 strengths · Avg: 8.8/10
Operating MarginProfitability
35.6%10/10

Strong operational efficiency at 35.6%

Market CapQuality
$158.18B9/10

Large-cap with strong market position

Profit MarginProfitability
24.4%9/10

Keeps 24 of every $100 in revenue as profit

Debt/EquityHealth
0.269/10

Conservative balance sheet, low leverage

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
27.0%8/10

Revenue surging 27.0% year-over-year

BMEZ2 strengths · Avg: 10.0/10
P/E RatioValuation
5.7x10/10

Attractively priced relative to earnings

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Areas to Watch

BLK4 concerns · Avg: 2.8/10
P/E RatioValuation
25.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Free Cash FlowQuality
$-1.19B2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
1.132/10

Distress zone — elevated risk

BMEZ4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$904.39M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
5.7%3/10

ROE of 5.7% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BLK

The strongest argument for BLK centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 24.4% and operating margin at 35.6%. Revenue growth of 27.0% demonstrates continued momentum.

Bull Case : BMEZ

The strongest argument for BMEZ centers on P/E Ratio, Debt/Equity.

Bear Case : BLK

The primary concerns for BLK are P/E Ratio, Piotroski F-Score, Free Cash Flow.

Bear Case : BMEZ

The primary concerns for BMEZ are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

BLK profiles as a growth stock while BMEZ is a value play — different risk/reward profiles.

BLK is growing revenue faster at 27.0% — sustainability is the question.

BMEZ generates stronger free cash flow (79M), providing more financial flexibility.

Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BLK scores higher overall (78/100 vs 30/100), backed by strong 24.4% margins and 27.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BlackRock Inc

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock, Inc. is an American multinational investment management corporation based in New York City.

BlackRock Health Sciences Trust II

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock Health Sciences Trust II (BMEZ) is a closed-end fund designed to deliver high total returns by investing in a diversified portfolio focused primarily on the health sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices. Backed by BlackRock's extensive investment management experience, BMEZ seeks to capitalize on substantial growth prospects driven by demographic shifts and increasing healthcare spending. The fund's disciplined and strategic investment approach positions it as a compelling choice for institutional investors looking to enhance their portfolios while navigating the dynamic and innovative landscape of the health sciences industry.

Want to dig deeper into these stocks?